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Morbidity and mortality from lung cancer is a major
burden to global health. The Cochrane Library
produces evidence-based systematic reviews to
facilitate sound decision-making. All published
reviews and protocols from the Lung Cancer
Cochrane Review Group (LCCRG) to date are listed
in Table 1. Full details of all reviews and protocols
are available from the Cochrane Library www.
cochrane.org/index0.htm and the LCCRG, which is
based in Barcelona, Spain. Thirteen reviews and 11
protocols have now been published, a surprisingly
small number considering the burden of disease
from lung cancer and the international effect ofElsevier Ltd. All rights reserv
rane reviews cited in this evid
of Thoracic Medicine, The Pri
.qld.gov.au (K.M. Fong).this highly lethal disease. Traditionally, the poor
outcomes in lung cancer has given rise to ther-
apeutic nihilism, and it is important to consider the
potential ability of evidence-based systematic re-
views to counter this view, to enable patients to
obtain the most effective therapies available.
Lung cancer trials lend themselves well to
systematic reviews. A large number of clinical
trials have been, or are being, conducted in lung
cancer. Some of these trials are large, others small.
Adequately powered, large and complex clinical
trials are often needed to find answers to key
research questions. Large trials are, however,
expensive and time-consuming. As always, clinical
trials should address the most pressing researched.
ence-based review.
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high to ensure that findings are reliable and valid.
Carefully conducted and presented systematic re-
views and, where appropriate, meta-analyses of
current evidence, are invaluable for further assim-
ilating clinical trial data into routine clinical
practice.
Here, we summarize the hard work of the
reviewers who have contributed to the LCCRG.
We identify selected examples of systematic re-
views to highlight their potential contribution
towards guiding clinicians in managing patients
with lung cancer. The reviewers’ conclusions are
summarized, although we have purposely avoided
duplicating the detailed data (odds ratios, con-
fidence intervals and P values).Prevention and screening
Smoking cessation
Extensive data on effective interventions are
addressed by Cochrane reviews (Cochrane Library
search term: ‘‘smoking cessation’’), and are outside
the scope of this review. However, effective
smoking cessation and prevention remains the
cornerstone of reducing future lung cancer morbid-
ity and mortality.
Chemoprevention
Chemoprevention involves using natural or syn-
thetic chemical agents to reverse, suppress or
prevent carcinogenic progression to invasive can-
cer. Drugs for preventing lung cancer in healthy
people is the subject of the review by Caraballoso
et al.,1 who reviewed four randomised-controlled
trials (RCTs) of chemoprevention. They concluded
that there was no evidence in support of vitamins
(i.e. alpha-tocopherol, beta-carotene or retinol)
alone, or in combination, to prevent lung cancer. In
fact, in one study, a harmful effect was found for
beta-carotene with retinol at pharmacological
doses in people with risk factors for lung cancer.
At present, no agent (or agents) seems to be
effective, and therefore none is recommended for
preventing lung cancer other than for use in clinical
trials. It is hoped that, one day, effective chemo-
prevention will be able to reduce the individual risk
of lung cancer in smokers, as well as former
smokers, who, as a result of effective tobacco
control campaigns, represent a growing number of
people remaining at risk. There is also a renewed
push towards better knowledge of the biology andmolecular (genetic and epigenetic) mechanisms of
early lung carcinogenesis. This will hopefully
translate into the design of effective chemopre-
ventative agents and future clinical trials. Modern
candidates include resveratrol (inhibitors of cy-
clooxygenase-2) and members of the ras-signaling
pathway and tyrosine kinase growth-factor recep-
tor pathways.
Screening
Manser et al.2 have reviewed screening for lung
cancer. The final aim of screening studies is to
reduce mortality. Characteristically, these studies
need to account for potential lead and length time
bias as well as over-diagnosis bias. Current evi-
dence from seven trials does not support screening
for lung cancer with chest radiography or sputum
cytology. Another, more recent, large, randomised
chest radiograph study (the US PLCO study) has
completed recruitment, but results will not be
available for some years.
Meanwhile, new technologies have been devel-
oped, such as low-dose spiral (helical) computed
tomography (CT), which are much more sensitive in
detecting nodules than chest radiographs. Research
on screening with CT continues to expand rapidly.
Although early results of uncontrolled cohort
studies are promising, these studies are potentially
susceptible to the same screening biases as chest-
radiography screening. Moreover, the cost-effec-
tiveness of CT screening for lung cancer will also
need to be addressed if effectiveness is confirmed.
However, in some countries, open-access CT scans
are available, including whole-body CT scanning.
Given the potential risk of radiation doses from CT,
high-level evidence of potential benefit is urgently
needed.Treatment
Non-small cell lung cancer
Surgery
Surgical resection of non-small cell lung cancer
(NSCLC) is traditionally recommended as the most
effective form of treatment in appropriate (i.e.
medically fit), early stage patients. The evidence
on surgery for early stage NSCLC is to be tested
formally in a new Cochrane protocol by Manser
et al.3 The aim of this review is to establish
whether surgical resection improves mortality, and
different surgical approaches will be compared for
effectiveness. Whether sufficient data will be
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Table 1 Systematic reviews and protocols from the Lung Cancer Cochrane Review Group.
Management
strategy
Cochrane review Cochrane protocol
Prevention and screening
Chemoprevention
strategies
Drugs for preventing lung cancer in
healthy people1
Screening Screening for lung cancer2
NSCLC
Surgical resection — Surgery for early stage NSCLC3
Surgery versus radiosurgery for patients
with a solitary brain metastasis from
NSCLC4
Complications of
surgery
Surgical sealant for preventing air leaks
after pulmonary resections in patients
with lung cancer5
Radiotherapy Radical radiotherapy for stage I/II NSCLC
in patients not sufficiently fit for or
declining surgery (medically inoperable)6
Cranial irradiation for preventing brain
metastases of NSCLC in patients at high
risk of cerebral metastases9
Concurrent chemoradiotherapy in NSCLC16
Chemotherapy Chemotherapy for NSCLC10 Gemcitabine for NSCLC13
Second-line chemotherapy for NSCLC11 Neoadjuvant chemotherapy for NSCLC12
Taxanes for advanced (metastatic and
locally advanced) NSCLC14
Adjuvant therapy Postoperative radiotherapy for NSCLC7
Management
strategy
Cochrane review Cochrane protocol
SCLC
Chemotherapy Chemotherapy versus best supportive care
for extensive SCLC17
Radiotherapy Early versus late chest radiotherapy for
limited stage SCLC18
Prophylactic
cranial irradation
Cranial irradiation for preventing brain
metastases of SCLC in patients in
complete remission20
Palliative care
Management of
symptoms
— Non-invasive interventions for improving
well-being and quality of life in patients
with lung cancer18
Chinese herbs for symptom palliation in
patients with lung cancer25
Malignant pleural
effusion
Pleurodesis for malignant pleural
effusions22
Palliative
chemotherapy
— Second or third additional chemotherapy
drug for NSCLC in patients with advanced
disease15
Palliative
radiotherapy
Palliative radiotherapy regimens for
NSCLC21
Palliative endobronchial brachytherapy
for NSCLC23
Superior vena cava
obstruction
Steroids, radiotherapy, chemotherapy and
stents for superior vena caval obstruction
in carcinoma of the bronchus24
NSCLC: non-small cell lung cancer; SCLC: small-cell lung cancer.
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RCTs have compared surgery in early stage lung
cancer (one study of surgery compared with radio-
therapy to our knowledge).
A protocol for a Cochrane review has been
published on the role of surgery compared with
radiosurgery for patients with a solitary brain
metastasis from NSCLC.4 This is an important
question in this subset of patients, as solitary brain
metastases may be problematic. The timing of
surgery, particularly in relation to securing control
of the primary site, is a key point.
The complication of persistent airleak after
surgery is common in patients with bullous lung
disease. Rami and Mateu5 have reviewed surgical
sealant for preventing air leaks after pulmonary
resections in patients with lung cancer. Data from
four trials indicate that systematic use of surgical
sealants in clinical practice cannot be recom-
mended at present.
Patients with early stage disease not suitable for
surgery (medically inoperable)
Despite modern advances in critical care, many
patients are unable to undergo surgery for poten-
tially resectable conditions because of the high
frequency of significant comorbid conditions. The
review of radical radiotherapy for patients with
stage I/II NSCLC, who are not sufficiently fit for, or
decline surgery (medically inoperable), supports
this modality of treatment.6 In such patients,
radical radiotherapy results in better survival
compared with no treatment. However, the re-
viewers reported that no RCTs have compared
immediate radical radiotherapy with palliative
radiotherapy given when patients develop symp-
toms. Another consideration is whether the combi-
nation of chemotherapy with radiotherapy would
improve outcomes in this patient group.
Radiotherapy
The role of postoperative radiotherapy (PORT) is
controversial, and practice seems to vary between
centres. This is reflected in the varying frequencies
documented in recent trials. In a review on PORT
for NSCLC,7 data from 2128 patients in nine trials
showed that PORT is detrimental to patients with
early stage, completely resected NSCLC, and
should not be used in the routine treatment of
such patients. A significant adverse effect on
survival was seen with PORT, with a 21% relative
increase in the risk of death. This was equivalent to
reducing overall survival at 2 years from 55% to
48%. Exploratory sub-group analyses suggested that
this detrimental effect was most pronounced for
patients with stage I/II, N0-N1 disease. On theother hand, the PORT meta-analysis listed the
relatively recent RCT on pathological Stage I NSCLC
as a study awaiting assessment, and this indicated a
small trend towards a survival benefit.8 The role of
PORT in the treatment of the N2 tumour subset is
not entirely clear. Although there was no survival
difference, there did seem to be an improvement in
local control. It has been argued that modern
treatment planning and technology may be able to
reduce the fatal toxicity observed in the PORT
meta-analysis. Also, traditionally, PORT has been
considered useful in patients with incomplete
resection of the primary cancer.
Lester et al.9 have published a protocol on the
importance of cranial irradiation for preventing
brain metastases of NSCLC patients at high risk of
cerebral metastases. This is clearly an important
issue, as the brain is a relatively common site of
relapse after potentially curative intent therapy for
NSCLC. Furthermore, brain metastases frequently
cause major symptomatology and reduce quality of
life. The rationale for prophylactic cranial radiation
is taken from small-cell lung cancer (SCLC), where
its risk–benefit profile seems better established
(see below).Chemotherapy for non-small cell lung cancer
Chemotherapy for the treatment of NSCLC has been
much debated. The controversy is compounded by
issues of costs relating to toxicity for patients and
the economic burden on the community. None-
theless, this Cochrane review on chemotherapy for
NSCLC extends the landmark meta-analysis of
1995.10 Results from 52 trials and 9387 patients
were included. Studies of modern regimens con-
taining cisplatin favoured chemotherapy, and
reached conventional levels of statistical signifi-
cance when used with radical radiotherapy and
with supportive care. Trials comparing surgery with
surgery plus chemotherapy showed a 13% reduction
in the risk of death, equivalent to an absolute
benefit of 5% at 5 years, improving survival from
50–55%. Indeed, this is an area of rapid advance-
ment, with further support arising from publication
of the recent European IALT adjuvant chemother-
apy study and presentation of two adjuvant studies
from North America at the 2004 ASCO meeting.
Promising data concerning an alternative adjuvant
regimen using long-term uracil-tegafur in Japanese
patients is also in the pipeline.
Trials comparing radical radiotherapy with radi-
cal radiotherapy plus chemotherapy gave a 13%
reduction in the risk of death equivalent to an
absolute benefit of 2% at 5 years, improving survival
from 5% to 7%.
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care plus chemotherapy gave a 27% reduction in the
risk of death equivalent to a 10% improvement in
survival at 1 year, improving survival from 15% to
25%, or an increased median survival of 1.5 months,
improving median survival from 4 to 5.5 months.
The reviewers conclude that these results offer
hope of progress, and suggest that chemotherapy
has a role in treating NSCLC. The real challenges
are to keep pace with the rapid development of
novel chemotherapy agents, as well as new
biologically based targeted therapies, and also to
consider quality-of-life issues with such an inter-
vention where the survival gains are modest and
serious toxicity, a possible risk. In practice, it is
essential to involve patients in discussion of the
risk–benefit ratio to accommodate the significant
variation in patient preferences in the decision-
making process.
Second-line chemotherapy for NSCLC has also
been reviewed.11 As most cases of NSCLC will
relapse after first-line chemotherapy, the question
of whether or not second-line chemotherapy is
effective and cost-effective is important for in-
dividual patient care, health providers and funders.
Bonfill et al.11 concluded that definitive recom-
mendations could not be made, as only one RCTwas
available at the time. Although it is of reasonable
quality, it had some limitations. It was suggested
that no current evidence was available to support
second-line treatment of patients with poor per-
formance status. Larger, well-designed controlled
trials are needed to further evaluate whether the
benefits of second-line chemotherapy to patients
with NSCLC outweigh its risks and costs.
Further protocols on the theme of chemotherapy
will examine neoadjuvant chemotherapy,12 gemci-
tabine for NSCLC13 and taxanes,14 and other second
or third-line chemotherapy15 for advanced (meta-
static and locally advanced) NSCLC.Concurrent chemotherapy and radiation
The review on concurrent chemoradiotherapy in
NSCLC analysed 14 trials of chemoradiotherapy
compared with radiotherapy alone.16 The pooled
data showed that concurrent chemoradiotherapy
produced a 14% reduction in risk of death at 2 years
compared with sequential chemoradiotherapy, and
a 7% reduction compared with radiotherapy alone,
albeit with an increase in acute oesophagitis.
The reviewers advised caution in adopting con-
current chemoradiotherapy as the standard of care
because of uncertainties about the true magnitude
of benefit compared with sequential chemora-
diotherapy.In some countries, delivery of concurrent che-
moradiation may be affected by external factors,
such as timely access to linear accelerator facilities
and appropriately skilled personnel, whereas che-
motherapy may be more widely available.Small cell lung cancer
Radiotherapy and chemotherapy
Radiotherapy and chemotherapy play significant
roles in the management of SCLC. The review on
chemotherapy versus best supportive care for
extensive SCLC included two studies, and found
that chemotherapy prolongs mean survival (be-
tween 66 and 79 days) in patients with advanced
SCLC, although the effect on quality of life is as yet
unknown.17 The findings from this review support
the use of chemotherapy in SCLC, where symptom
control is also a relevant end point.
It is generally accepted from RCTs and previous
meta-analyses that thoracic radiotherapy plays an
important role in patients receiving radical treat-
ment for SCLC. Some, but not all, studies suggested
benefit for initial rather than later radiotherapy.
The recently published Cochrane review18 on early
versus late chest radiotherapy for limited stage
SCLC reviewed seven RCTs. Notably, there were
differences between trials in the timing and
duration of chest radiotherapy and the type of
chemotherapy used; the largest trial includes 3-
year follow-up data. The reviewers found no
significant differences in 2- or 5-year survival,
whether chest radiotherapy was delivered within
30 days of the start of chemotherapy or later.
Excluding the single study of chest radiotherapy
concurrent with non-platinum chemotherapy, a
trend in favour of early radiation was observed in
5-year survival (relative risk: 0.93, P ¼ 0:07), but
not in 2-year survival. The results also suggested
that survival at 5 years (but not 2 years) was
significantly better when early chest radiotherapy
was delivered within 30 days compared with more
extended treatment time (relative risk: 0.90,
P ¼ 0:006). Local control was not significantly
different between early and late chest radio-
therapy. No differences were found in local tumour
control, incidence of severe oesophagitis or inci-
dence of severe pneumonitis between early com-
pared with late thoracic radiotherapy. However, a
trend towards increased risk of pneumonitis was
observed with early chest radiotherapy concurrent
with non-platinum-based chemotherapy.
Hyperfractionation scheduling of thoracic radio-
therapy in patients receiving treatment for SCLC
has also been proposed on the basis of one RCT that
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expressed concern about the treatment duration in
the control arm.19
At the other end of the spectrum, uncertainty
about prophylactic cranial irradiation for preven-
tion of brain metastases in patients with SCLC in
complete remission is also helped by the review on
this topic.20 Metastatic brain disease is undoubt-
edly an important cause of treatment failure within
this subset of patients. Data pooled from seven
trials showed that prophylactic cranial irradiation
significantly improves survival and disease-free
survival for patients with SCLC in complete remis-
sion, with an overall 5% increase in the 3-year
survival rate (from 15% in the control group to 21%
in the treatment group).
Palliative care and complications
Radiotherapy delivery can be limited by the
availability of linear accelerators or the skilled
staff to run them. Clearly, the more the radio-
therapy fractions that are required, the higher the
demand on the systems. The review on palliative
radiotherapy regimens for NSCLC is important for
clinical management issues and also for its implica-
tions for health utilisation and planning.21 The
reviewers concluded that most of the patients
should be treated with short courses of palliative
radiotherapy, of one or two fractions, whereas the
use of high-dose palliative regimens can be
considered for selected patients with good perfor-
mance status.
Malignant pleural effusions are particularly com-
mon and cause significant morbidity in lung cancer.
As they can be managed with a variety of methods,
ranging from simple drainage to surgical interven-
tion, the review on pleurodesis for malignant
pleural effusions22 is highly relevant. This review
analysed RCTs of adults undergoing pleurodesis for
pleural effusion caused by metastatic malignancy
or a malignant process leading to pleural effusion.
The data support the need for chemical sclerosants
for successful pleurodesis, the use of talc as the
sclerosant of choice, and thoracoscopic pleurodesis
as the preferred technique for pleurodesis.
Although not restricted to lung cancer, these
findings are likely to be generally applicable, with
the possible exception of cases of trapped lung or
large airway obstruction, in which most techniques
are less likely to be effective. In the case of large
airway obstruction, palliative endobronchial bra-
chytherapy for NSCLC will be evaluated in a
forthcoming review.23
Superior vena cava obstruction has been de-
scribed as a medical emergency, requiring urgent
therapy. In the review on steroids, radiotherapy,chemotherapy and stents for superior vena caval
obstruction in carcinoma of the bronchus,24 data
from randomised and non-randomised trials indi-
cated that chemotherapy and radiotherapy are
effective in relieving superior vena caval obstruc-
tion in 70% of patients, whereas stent insertion
seems to provide relief in 95% of patients and more
rapidly. These results are relevant, as each of these
treatment modalities requires particular specialist
skills and equipment, and availability may differ
among different health-care facilities.
Quality-of-life considerations are important in
the palliative care of patients with lung cancer. A
protocol has been published on non-invasive inter-
ventions for improving well-being and quality of life
in patients with lung cancer.18 Indeed, high-quality
modern clinical trials invariably include quality of
life as outcome measures, and we look forward to
these measures being incorporated into forthcom-
ing Cochrane reviews. These measures will provide
insight into therapeutic toxicity lung cancer,
particularly in the context of improvements to
survival, which are sometimes only relatively
modest.Complementary therapy
The role of complementary therapy is being
evaluated in the protocol on Chinese herbs for
symptom palliation in patients with lung cancer.25
This is the first review on lung cancer to address
complementary medicines. Alternative or comple-
mentary medicines are increasingly being used
around the world for the relief of cancer-related
symptoms, such as acupuncture, mind–body tech-
niques and massage therapy. To ensure the effec-
tive and cost-effective use of complementary
medicines, further Cochrane reviews encompassing
this approach are likely to be valuable. The
challenge for investigators and reviewers in this
area is that even broadly similar alternative
medicines or therapeutic techniques often vary
significantly in delivery, composition or dosage,
presenting methodological difficulties in meta-
analyses.The lung cancer cochrane review group
The LCCRG (www.cochrane.es/LCG) produces a
regular newsletter for interested stakeholders.
Recently, identified future ‘‘hot topics’’ have been
proposed for forthcoming reviews, including photo-
dynamic therapy for lung cancer, steroids for
control of dyspnoea in advanced lung cancer,
steroids for radiation pneumonitis, induction
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new biological agents for lung cancer, minimal lung
resections for lung cancer patients with poor lung
function, extensive nodal dissection during curative
surgery for NSCLC, vinca alkaloids for NSCLC,
elective mediastinal irradiation in stage I–II NSCLC
treated by radical radiotherapy, biological growth
modifying agents in NSCLC (especially in elderly
people and those with poor performance status),
increased dose-intensity for SCLC, increase in
number of agents for SCLC, platinum versus non-
platinum agents for SCLC, chemoradiotherapy for
SCLC, surgery plus chemoradiotherapy for SCLC.
We look forward to future updates of existing
reviews and reviews of new topics to guide and
inform best evidence-based management of pa-
tients at risk or diagnosed with lung cancer.Conclusion
The stated aims of the LCCRG are to keep abreast
of all recent developments in the prevention,
treatment and palliation of lung cancer, and to
publish relevant and timely systematic reviews of
the evidence covering the entire scope of inter-
ventions for lung cancer. To this end, the LCCRG is
to be commended on the quality and significance of
reviews to date, as well as their plans to increase
the number of reviewed topics. Credit must also go
to all the LCCRG reviewers from all over the world
for their hard work and commitment towards this
effort.
Future success will rely on the ability to update
completed reviews, maintain an output of reviews
that reflect current clinical trial research, monitor
new developments in research and clinical prac-
tice, recruit authors of sufficient multidisciplinary
expertise and skills, and provide the necessary
training and support. High-quality reviews can only
help improve the quality of care for the large
numbers of people with or at risk of developing lung
cancer.
A practical challenge for the effective imple-
mentation of systematic reviews is to translate the
painstakingly analysed, precise data, often laced
with technical and statistical jargon, into clinically
applicable, readily understood information that has
value at the bedside or clinical setting.
The effect of reviews in real life is clearly also
dependent on accessibility to readers and consu-
mers. Thus, the effort to make access to the
Cochrane Library free, is a small but crucial step in
disseminating evidence-based medicine into our
daily practice.In the meantime, we would encourage all
clinicians and health professionals interested in
evidence-based medicine and lung-cancer care to
consider partaking in a Cochrane review of lung-
cancer interventions, with the ultimate aim of
helping to make a difference in preventing and
treating this devastating cancer, which no one
deserves. Although researchers are able to carry
out independent systematic reviews or meta-
analyses, participation in a Cochrane review is able
to facilitate high-quality reviews by providing
access to Cochrane training, RevMan software,
technical assistance (e.g. search strategies) and
editorial advice and guidance for protocol devel-
opment and performance of the review. New and
updated reviews will help us all manage this
common and challenging disease.
Practice points
 Smoking cessation reviews are comprehen-
sively covered in the Cochrane Library—
prevention remains the most effective way
of reducing the affect of lung cancer
 Considering the large burden of disease, the
number of systematic reviews on lung
cancer is modest
 As the management of lung cancer is
complex, many systematic reviews are
appropriately focused on specific clinical
subgroups of patients
 Lung cancer trials lend themselves well to
systematic review
 Although the overall mortality from lung
cancer has improved marginally over years,
even small improvements in patient out-
comes have the potential to make substan-
tial improvements at the population level
because of the high incidence of diseaseResearch directions
 More systematic reviews are required to
consolidate evidence from lung cancer
trials, and to use the power of meta-
analysis to extract maximum value from
clinical trials, which are often relatively
small
 Attention needs to be paid to complemen-
tary medicine, which is often used alongside
or instead of conventional therapies
 The challenge of the LCCRG is to keep
abreast of the large number of new
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across the spectrum of oncology, while at
the same time updating current reviews to
reflect current literature
 Another challenge is to account for poten-
tial biological and molecular prognostic
factors during systematic reviews of ther-
apy (e.g. heterogeneity in treatment re-
sponse may be predictable by biomarkers,
which may or may not be measured or
balanced within studies)
 Strategies for generating high-quality re-
views and managing the volume of increas-
ingly topical subjects are needed
 Identifying methods of embedding systema-
tic review data into routine clinical practice
is an ongoing challengeConflict of interest: KF is a co-editor for the
Cochrane Lung Cancer review Group.References
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